Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PORTRAZZA vs ANTHIM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin.
FDA: Treatment of chronic lymphocytic leukemia (CLL) (not approved; withdrawn from market),Off-label: None
PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
Terminal elimination half-life is approximately 14 days (range 10–18 days). This long half-life supports dosing every 3 weeks and allows sustained receptor blockade.
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Metabolism of necitumumab has not been fully characterized. As a monoclonal antibody, it is expected to be degraded into small peptides and amino acids via general protein catabolic pathways.
Metabolized by exonucleases to shorter oligonucleotides.
Necitumumab is an Ig G1 monoclonal antibody; elimination occurs via intracellular catabolism, with no significant renal or biliary excretion. No specific percentage of elimination via renal or fecal routes is established.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Necitumumab is a monoclonal antibody; target-mediated binding to EGFR occurs, but nonspecific plasma protein binding is negligible. No specific protein binding percentage is reported.
Approximately 57% bound to plasma proteins (including albumin and immunoglobulins)
Volume of distribution at steady state is approximately 5.8 L (range 4.7–7.1 L), suggesting distribution primarily in the vascular space and minimal extravascular distribution.
Volume of distribution: approximately 0.16–0.20 L/kg; indicates limited extravascular distribution, consistent with a monoclonal antibody
Intravenous: 100% (not applicable to other routes).
Intravenous: 100% bioavailability; no other routes are approved or clinically relevant
No dose adjustment is recommended for patients with mild to moderate renal impairment. There is no data for severe renal impairment (Cr CL <30 m L/min) or end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No formal studies have been conducted in patients with hepatic impairment. No dose adjustment is recommended for mild hepatic impairment (Child-Pugh A). Use caution in moderate to severe hepatic impairment due to lack of data.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C).
Safety and effectiveness in pediatric patients have not been established.
For patients weighing 10 kg to <40 kg: 14 mg/kg IV (max 800 mg) over 90 minutes, then 7 mg/kg IV (max 400 mg) over 90 minutes at 2 and 4 weeks post-first dose. For patients ≥40 kg: same as adult dosing.
No specific dose adjustment is recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy were observed compared to younger patients.
No specific dose adjustment recommended; clinical studies did not include sufficient numbers of patients aged ≥65 years to determine whether they respond differently. Use with caution.
No black box warnings.
None.
Cardiopulmonary arrest and/or sudden death occurred in 3% of patients receiving necitumumab in combination with gemcitabine and cisplatin; monitor electrolytes and consider withholding for severe electrolyte abnormalities.,Arterial thromboembolic events (ATEs) occurred in 5% of patients; permanently discontinue for serious ATEs.,Venous thromboembolic events (VTEs) including pulmonary embolism occurred; permanently discontinue for life-threatening VTEs.,Hemolytic-uremic syndrome (HUS) reported; discontinue if HUS is suspected.,Dermatologic toxicities including rash, dry skin, and pruritus; monitor and manage accordingly.,Infusion-related reactions; interrupt or discontinue for severe reactions.,Hypomagnesemia occurred in 83% of patients; monitor magnesium, calcium, and potassium prior to each dose.,Embryofetal toxicity: can cause fetal harm; advise females of reproductive potential of effective contraception.
Myelosuppression,Infusion reactions,Tumor lysis syndrome,Electrolyte abnormalities,Cardiotoxicity
No known contraindications from the manufacturer.
Hypersensitivity to oblimersen or any component of the formulation
No specific food interactions have been identified with necitumumab. However, maintain adequate hydration and nutrition. Grapefruit and other CYP3A4 inhibitors are not expected to interact since necitumumab is a monoclonal antibody cleared via proteolysis.
No known food interactions. ANTHIM is administered intravenously, and food intake does not affect its pharmacokinetics.
Portrazza (necitumumab) is an Ig G1 monoclonal antibody. Ig G molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to therapeutic concentrations. There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (EGFR inhibition), there is a risk of fetal harm, including developmental abnormalities and fetal loss. Women of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose.
ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data is limited. As a Ig G1 monoclonal antibody, it is expected to cross the placenta increasingly after the first trimester. The risk is likely low but cannot be excluded. Use only if clearly needed.
It is not known whether necitumumab is excreted in human milk. Human Ig G is known to be present in milk, but the amount is generally low. Due to the potential for serious adverse reactions in nursing infants, advise women not to breast-feed during treatment and for at least 3 months after the last dose. M/P ratio is unknown.
It is not known whether obiltoxaximab is excreted in human milk. Monoclonal antibodies are typically excreted in breast milk at low levels with limited oral bioavailability due to gastrointestinal degradation. The M/P ratio is unknown. Caution should be exercised, but benefits of breastfeeding and maternal therapy should be considered.
No specific dosing adjustments for pregnancy are established. However, physiological changes during pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics. Currently, no dose modification is recommended due to lack of data; however, caution is advised, and treatment should only be used if the potential benefit justifies the potential risk to the fetus.
No dose adjustment is required for ANTHIM based on pregnancy. Pharmacokinetic studies in pregnant women are not available; however, pregnancy-related changes in volume of distribution and renal clearance may alter drug levels, but clinical significance is unknown. Standard adult dosing is recommended.
PORTRAZZA (necitumumab) is a human Ig G1 monoclonal antibody targeting EGFR. Prior to initiation, confirm EGFR expression in squamous non-small cell lung cancer. Premedicate with H1 antagonists to reduce infusion-related reactions. Monitor for hypomagnesemia, which can occur weeks after treatment; replete as needed. Avoid use in patients with a history of severe infusion reactions to other EGFR inhibitors.
ANTHIM (obiltoxaximab) is a monoclonal antibody indicated for inhalational anthrax. It should be administered as soon as possible after suspected or confirmed exposure. Premedication with diphenhydramine may reduce infusion reactions. Monitor for anaphylaxis and infusion-related reactions. Efficacy is established in animal models due to ethical limitations.
Inform your doctor if you experience severe skin rash, diarrhea, or infusion reactions during treatment.,Report any signs of low magnesium such as muscle cramps, numbness, or irregular heartbeat.,Avoid sun exposure and use broad-spectrum sunscreen SPF 50+; this drug increases photosensitivity.,Do not receive live vaccines while on PORTRAZZA.,Use effective contraception during treatment and for 3 months after the last dose if you are of childbearing potential.
ANTHIM is used to treat or prevent inhalational anthrax, which can be fatal if not treated.,You will receive this medication as an intravenous (IV) infusion over 1.5 hours.,You may experience side effects such as pain or swelling at the infusion site, headache, itching, or feeling tired.,Serious allergic reactions can occur; tell your healthcare provider immediately if you develop rash, hives, difficulty breathing, or swelling of the face or throat.,Because ANTHIM is made from mouse proteins, it can cause allergic reactions in some people.,This medication should not replace a recommended vaccination program for anthrax.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PORTRAZZA vs ANTHIM, answered by our medical review team.
PORTRAZZA is a Antineoplastic Monoclonal Antibody that works by PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.. ANTHIM is a Monoclonal Antibody that works by Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PORTRAZZA and ANTHIM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PORTRAZZA is: PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.. The standard adult dose of ANTHIM is: 800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PORTRAZZA and ANTHIM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PORTRAZZA is classified as Category C. Portrazza (necitumumab) is an IgG1 monoclonal antibody. IgG molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to the. ANTHIM is classified as Category C. ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.